XII.

DISCHARGE PLAN

M-Medications to continue at home

NAME
OF MEDICINE
1. Cefuroxime

2. NeoPenotran

3. Maalox

4. Sangobian

PURPOSE

AMOUNT/DOSE

Treatment of susceptible infections which

include bone and joint infections,
bronchitis (and other lower respiratory
tract infections), gonorrhea, meningitis
(although treatment failures have been
reported in H. influenzae meningitis), otitis
media, peritonitis, pharyngitis, sinusitis,
skin infections (including soft tissue
infections) and urinary tract infections.
Injection: Prophylaxis for surgical infection.

500mg/tab

FREQUENCY/ROUTE/
DURATION
PO/ BID X 7days

Treatment of vaginal candidiasis caused

by Candida albicans, bacterial vaginitis
caused by anaerobic bacteria
and Gardnerella vaginalis, trichomonal
vaginitis caused by Trichomonas
vaginalis and mixed vaginal infections.
-Symptomatic relief to upset stomach
associated hyperacidity
-Hyperacidity associated with peptic ulcer,
gastritis, peptic esophagatis, gastric hyper
acidity, and hiatal hernia
-Short-term relief of constipation,
evacuation of the colon for rectal
andbowel examination
-Cap: Fe-deficiency anemia & anemia
during growth, old age & convalescence;
megaloblastic anemia during pregnancy,
in sprue or parasitosis; anemia due to

100mg/suppository

Suppository x 3 days

1 tab

1 hr post meal & bedtime

1 cap

QD

5. Prednisome

6. Aspilet

general dietary insufficiency; anemia

prophylaxis in blood donors. Prevention of
maternal constipation due to pregnancy &
Fe intolerability. Syr: Fe-deficiency anemia
in childn, latent insufficiency of Fe & vit B;
in chronic illnesses & during
convalescence. Drops: Fe & folic acid
supplement for anemia during growth
period.
-Replacement o therapy in adrenal cortical
sufficiency
-Hypercalcemia associate with cancer
-Short-term management of various
inflammatory and allergic disorders, such
as rheumatoid arthritis, collagen disease,
dermatologic disease, status asthmaticus
and autoimmune disorders.
Mild to moderate pain
Fever
Inflammatory conditions- rheumatic fever,
rheumatoid arthritis, osteoarthritis,
juvenile rheumatoid arthritis,
spondyloarthropathies
Reduction of risk of recurrent TIAs or
stroke in patients with history of TIA due to
fibrin platelet emboli or ischemic stroke
Reduction of risk of death or nonfatal MI in
patients with history of infarction or
unstable angina pectoris or suspected
acute MI
Patients who have undergone
revascularization procedures
Unlabeled uses: Prophylaxis against
cataract formation with long-term use;
prosthetic valve thromboprophylaxis,

10mg/tab

1 tab QD

80mg/tab

1 tab QD

Kawasaki disease, antithrombotic therapy

in children with Blalock-Taussig shunt an
after Fontan procedure

E-Exercises

Not applicable; strictly for bedrest

T-Treatment

For urinalysis after 7 days intake of Cefuroxime

H-Health Teaching
Title: Health teaching about prevention and treatment of urinary tract infection
Learning Objectives

Learning content

After the discussion, the

client will be able to know
how to prevent and treat
urinary tract infection.

The
discussion
will
include the following:

Definition of UTI

Signs
and
symptoms

Causes of UTI

Complications of
UTI

Tests
and
diagnosis.

Treatment of UTI.

Prevention of UTI.

Time
allotment
The discussion
will last for
25-30
minutes.

Strategy/
Methodology

Assess
the
current
knowledge of the
client
about
urinary
tract
infections
Give the client a
brochure
or
handout
containing all the
information that
will be discussed.
Encourage active

Resources
http://www.mayocli
nic.org/diseasesconditions/urinarytractinfection/basics/de
finition/con20037892

Evaluation

participation
of
the
client
by
asking questions
during
the
discussion.

Comment/s:
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________

O-Out Patient
DOCTORS
NAME
Dr. Vega
Dr. Baes

DATE

TIME

After 1 week
Once with Urinalysis
result

D-Diet

Diet as tolerated then Non per orem if with hypogastric pain

S-Sexuality/Spirituality

Abstinence in sexual intercourse

CLINICS
LOCATION
FEU-NRMF
FEU-NRMF

CLINICS TEL. NO.

427-0213
427-0213